Pace Life Sciences to Lead Discussion on Targeted Drug Delivery at Oligo & Peptides HubXchange

Pace Life Sciences, a prominent contract development and manufacturing organization (CDMO) within the Pace portfolio, is gearing up to participate in the Oligo & Peptides HubXchange event. Scheduled for April 30 in Boston, the event will feature Dr. Peter Abbink, an expert at Pace Life Sciences, as the facilitator for the roundtable session titled “Strategies for Targeted Drug Delivery.”

Advancing Targeted Therapeutics

This interactive session aims to gather industry leaders to discuss innovative methods and technological advancements that are shaping the landscape of targeted therapeutics, particularly in the realms of oligonucleotides, peptides, and genetic medicines. The focus will be on the challenges and breakthroughs that are critical to the evolution of these specialized therapies.

Key Discussion Topics

Several pivotal issues will be addressed during the roundtable, including:

• Next-Generation Delivery Systems: Exploring novel lipid nanoparticles (LNPs) and innovative surface “decorating” techniques designed for precise tissue targeting.

• Safety and Efficacy Improvements: Examining strategies to avoid liver targeting, which could enhance the safety profile and overall effectiveness of therapies.

• Vector Comparisons: Evaluating the advantages of viral versus non-viral delivery methods for therapeutic agents.

• Manufacturing and Clinical Translation: Discussing the considerations necessary for scaling manufacturing and ensuring successful clinical translation of these therapies.

Dr. Abbink emphasizes the significance of targeted delivery, stating, “Targeted delivery remains one of the most critical challenges and opportunities in advancing next-generation therapeutics. This session will foster meaningful discussion on how emerging technologies can improve precision, reduce off-target effects, and accelerate the path to patients.”

Pace Life Sciences’ Commitment

Pace Life Sciences continues to be a cornerstone in the development and commercialization of complex therapeutics. The organization offers a comprehensive suite of integrated solutions encompassing analytical services, development, and manufacturing processes tailored to meet the unique needs of the pharmaceutical and biopharmaceutical sectors.

Leadership and Expertise

Dr. Abbink is recognized as a leading authority in biologics, gene therapies, and vaccine development. He currently manages operations at the Boston facility of Pace Life Sciences, where he drives advancements in small molecules, biologics, and innovative therapeutic strategies. Additionally, he holds the position of President at Vector Sciences, Inc., where he focuses on pioneering vaccine and gene therapy platforms. With over 70 publications and multiple patents to his name, Dr. Abbink’s expertise is invaluable to the industry.

Comprehensive CMC Services

Pace Life Sciences offers a full range of contract CMC development services, including manufacturing for clinical trial materials, regulatory compliance, and consulting. The organization boasts a network of GMP analytical testing laboratories and manufacturing support centers, staffed by experienced professionals dedicated to advancing client programs from the clinic to commercialization efficiently. Their commitment to providing reliable services ensures positive customer experiences across all business channels.

Corporate Philosophy

Pace is dedicated to making the world safer and healthier. Their team is passionate about advancing the science within the pharmaceutical and biotechnology sectors, supporting various stakeholders, including businesses, consulting firms, and government agencies. With a national laboratory network backing their local-level services, Pace empowers clients with the science and data necessary for making informed decisions that benefit society as a whole.

Takeaways

• Dr. Peter Abbink will lead a significant roundtable on targeted drug delivery at the Oligo & Peptides HubXchange.

• The discussion will focus on innovative delivery systems and their implications for the future of targeted therapeutics.

• Pace Life Sciences is committed to providing comprehensive solutions that enhance the development and manufacturing of complex therapies.

In conclusion, the upcoming HubXchange event presents a valuable opportunity for industry experts to converge and share insights on critical advancements in targeted drug delivery. Through these discussions, the potential for innovative therapies to reach patients more efficiently is significantly enhanced, reinforcing the vital role of organizations like Pace Life Sciences in the biotechnology landscape.

Read more → www.finanznachrichten.de